Effect of receptor for activated C kinase 1 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs
10.3760/cma.j.issn.1006-9801.2015.06.008
- VernacularTitle:活化的蛋白激酶C受体1基因沉默对肺腺癌A549细胞化疗敏感性的影响
- Author:
Jihui KANG
;
Kaili DU
;
Gang LIANG
;
Hong XIAO
;
Hongkun WANG
;
Jianfang LIANG
;
Huixia ZHENG
- Publication Type:Journal Article
- Keywords:
Lung adenocarcinoma A549 cells;
RACK1 gene;
RNA interference
- From:
Cancer Research and Clinic
2015;27(6):394-397,412
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of shRNA-mediated down-regulation of the receptor for activated C kinase 1 (RACK1) gene on the chemotherapeutic sensitivities in human lung adenocarcinoma cell line A549.Methods The shRNA recombinant plasmid targeting to human RACK1 gene was designed and transferred into A549 cells by lipofectin technique.The protein level of RACK1 was measured by Western blot to confirm the function of shRNA plasmid.Drug sensitivities of A549 cells to cisplatin,gemcitabine,pemetrexed and paclitaxel were analyzed by MTT assay.The protein expression of LRP and MRP were detected by Western blot.Results After 24 hours transfection,the relative expression quantity of RACK1 protein in RACK1-shRNA group was 0.267± 0.470,which was significantly lower than that in vector-shRNA group (0.821±0.109) and control group (0.842±0.060) (F =54.438,P ＜ 0.05).The results of MTT showed that the growth of A549 cells in the RACK1-shRNA group was markedly inhibited.The sensitivities of A549 cells to cisplatin and paclitaxel were significantly enhanced compared with that in the vector-shRNA group and control group (P ＜ 0.05).The relative expression quantity of LRP and MRP protein in RACK1-shRNA group were 0.163±0.056 and 0.246±0.050,which were lower than that in vector-shRNA group and control group (F LRP =19.430,F MRP =61.548,both P ＜ 0.05).Conclusion Targeted gene silencing of RACK1 improves the sensitivity of A549 cells to the ascisplatin and paclitaxel medicines,which might be achieved through down-regulation of the expression of LRP and MRP.
